OBJECTIVES: To estimate the impact of injecting drug use (IDU) on mortality in HIV-infected patients in the highly active antiretroviral therapy (HAART) era. DESIGN: Population-based, nation-wide prospective cohort study in Denmark (the Danish HIV Cohort Study). METHODS: A total of 4578 HIV-infected patients were followed from 1 January 1997 or date of HIV diagnosis. We calculated mortality rates stratified on IDU. One-, 5- and 10-year survival probabilities were estimated by Kaplan-Meier methods, and Cox regression analyses were used to estimate mortality rate ratios (MRR). RESULTS: Of the patients, 484 (10.6%) were categorized as IDUs and 4094 (89.4%) as non-IDUs. IDUs were more likely to be women, Caucasian, hepatitis C virus (HCV) co-infected and younger at baseline; 753 patients died during observation (206 IDUs and 547 non-IDUs). The estimated 10-year survival probabilities were 53.2% [95% confidence interval (CI): 48.1-58.3] in the IDU group and 82.1% (95% CI: 80.7-83.6) in the non-IDU group. IDU as route of HIV infection more than tripled the mortality in HIV-infected patients (MRR: 3.2; 95% CI: 2.7-3.8). Adjusting for potential confounders did not change this estimate substantially. The risk of HIV-related death was not increased in IDUs compared to non-IDUs (MRR 1.1; 95% CI 0.7-1.7). CONCLUSIONS: Although Denmark's health care system is tax paid and antiretroviral therapy is provided free of charge, HIV-infected IDUs still suffer from substantially increased mortality in the HAART era. The increased risk of death seems to be non-HIV-related and is due probably to the well-known risk factors associated with intravenous drug abuse.
OBJECTIVES: To estimate the impact of injecting drug use (IDU) on mortality in HIV-infectedpatients in the highly active antiretroviral therapy (HAART) era. DESIGN: Population-based, nation-wide prospective cohort study in Denmark (the Danish HIV Cohort Study). METHODS: A total of 4578 HIV-infectedpatients were followed from 1 January 1997 or date of HIV diagnosis. We calculated mortality rates stratified on IDU. One-, 5- and 10-year survival probabilities were estimated by Kaplan-Meier methods, and Cox regression analyses were used to estimate mortality rate ratios (MRR). RESULTS: Of the patients, 484 (10.6%) were categorized as IDUs and 4094 (89.4%) as non-IDUs. IDUs were more likely to be women, Caucasian, hepatitis C virus (HCV) co-infected and younger at baseline; 753 patients died during observation (206 IDUs and 547 non-IDUs). The estimated 10-year survival probabilities were 53.2% [95% confidence interval (CI): 48.1-58.3] in the IDU group and 82.1% (95% CI: 80.7-83.6) in the non-IDU group. IDU as route of HIV infection more than tripled the mortality in HIV-infectedpatients (MRR: 3.2; 95% CI: 2.7-3.8). Adjusting for potential confounders did not change this estimate substantially. The risk of HIV-related death was not increased in IDUs compared to non-IDUs (MRR 1.1; 95% CI 0.7-1.7). CONCLUSIONS: Although Denmark's health care system is tax paid and antiretroviral therapy is provided free of charge, HIV-infected IDUs still suffer from substantially increased mortality in the HAART era. The increased risk of death seems to be non-HIV-related and is due probably to the well-known risk factors associated with intravenous drug abuse.
Authors: Daniel Fuster; Debbie M Cheng; Emily K Quinn; David Nunes; Richard Saitz; Jeffrey H Samet; Judith I Tsui Journal: Addiction Date: 2013-10-24 Impact factor: 6.526
Authors: Serena P Koenig; Luis A Rodriguez; Courtenay Bartholomew; Alison Edwards; Tracie E Carmichael; Geoffrey Barrow; André Cabié; Robert Hunter; Giselle Vasquez-Mora; Avion Quava-Jones; Nicholas Adomakoh; J Peter Figueroa; Bernard Liautaud; Magaly Torres; Jean W Pape Journal: J Acquir Immune Defic Syndr Date: 2012-04-01 Impact factor: 3.731
Authors: Lindsey A Richardson; M-J S Milloy; Thomas H Kerr; Surita Parashar; Julio S G Montaner; Evan Wood Journal: J Epidemiol Community Health Date: 2013-10-23 Impact factor: 3.710
Authors: Margaret T May; Amy C Justice; Kate Birnie; Suzanne M Ingle; Colette Smit; Colette Smith; Didier Neau; Marguerite Guiguet; Carolynne Schwarze-Zander; Santiago Moreno; Jodie L Guest; Antonella dʼArminio Monforte; Cristina Tural; Michael J Gill; Andrea Bregenzer; Ole Kirk; Michael Saag; Timothy R Sterling; Heidi M Crane; Jonathan A C Sterne Journal: J Acquir Immune Defic Syndr Date: 2015-07-01 Impact factor: 3.731
Authors: Yan Zhao; Cynthia X Shi; Jennifer M McGoogan; Keming Rou; Fujie Zhang; Zunyou Wu Journal: Bull World Health Organ Date: 2013-02-01 Impact factor: 9.408
Authors: Nikoloz Chkhartishvili; Lali Sharvadze; Otar Chokoshvili; Natalia Bolokadze; Nino Rukhadze; Russell R Kempker; Amiran Gamkrelidze; Jack A DeHovitz; Carlos Del Rio; Tengiz Tsertsvadze Journal: AIDS Res Hum Retroviruses Date: 2014-02-24 Impact factor: 2.205
Authors: Anne Langkilde; Janne Petersen; Henrik Hedegaard Klausen; Jens Henrik Henriksen; Jesper Eugen-Olsen; Ove Andersen Journal: PLoS One Date: 2012-12-10 Impact factor: 3.240